127 related articles for article (PubMed ID: 21915022)
1. Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.
Neth O; Falcon-Neyra L; Ruiz-Valderas R; León Leal JA; Obando I; Alvarez Del Vayo Benito C; Lopez-Cortes LF
Pediatr Infect Dis J; 2011 Oct; 30(10):917. PubMed ID: 21915022
[No Abstract] [Full Text] [Related]
2. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.
Vernazza P; Daneel S; Schiffer V; Decosterd L; Fierz W; Klimkait T; Hoffmann M; Hirschel B
AIDS; 2007 Jun; 21(10):1309-15. PubMed ID: 17545707
[TBL] [Abstract][Full Text] [Related]
3. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.
Ghosn J; Carosi G; Moreno S; Pokrovsky V; Lazzarin A; Pialoux G; Sanz-Moreno J; Balogh A; Vandeloise E; Biguenet S; Leleu G; Delfraissy JF
Antivir Ther; 2010; 15(7):993-1002. PubMed ID: 21041914
[TBL] [Abstract][Full Text] [Related]
4. Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children.
Bunupuradah T; Kosalaraksa P; Puthanakit T; Mengthaisong T; Wongsabut J; Lumbiganon P; Phanuphak P; Burger D; Pancharoen C; Ananworanich J;
AIDS; 2011 Jan; 25(3):315-23. PubMed ID: 21157298
[TBL] [Abstract][Full Text] [Related]
5. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
[TBL] [Abstract][Full Text] [Related]
6. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
[No Abstract] [Full Text] [Related]
7. Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.
Meynard JL; Bouteloup V; Landman R; Bonnard P; Baillat V; Cabie A; Kolta S; Izopet J; Taburet AM; Mercie P; Chene G; Girard PM;
J Antimicrob Chemother; 2010 Nov; 65(11):2436-44. PubMed ID: 20843990
[TBL] [Abstract][Full Text] [Related]
8. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
[TBL] [Abstract][Full Text] [Related]
10. [Simplification to lopinavir/ritonavir monotherapy in HIV-infected children].
Mur-Sierra A; López-Segura N; López-Vílchez MA
An Pediatr (Barc); 2011 Jul; 75(1):51-4. PubMed ID: 21439924
[TBL] [Abstract][Full Text] [Related]
11. PI monotherapy effective as maintenance.
AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
[No Abstract] [Full Text] [Related]
12. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.
Sahali S; Chaix ML; Delfraissy JF; Ghosn J
AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of atazanavir in treatment-naive patients].
Moreno S; Hernández B; Dronda F
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.
Rusconi S; Giacomet V; Mameli C; Viganò A; Viganò O; Adorni F; Galli M; Zuccotti GV
BMC Infect Dis; 2012 Aug; 12():179. PubMed ID: 22866946
[TBL] [Abstract][Full Text] [Related]
16. Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.
Castagna A; Galli L; Gianotti N; Torti C; Antinori A; Maserati R; d'Arminio Monforte A; Quiros-Roldan E; Salpietro S; Lazzarin A
New Microbiol; 2013 Jul; 36(3):239-49. PubMed ID: 23912865
[TBL] [Abstract][Full Text] [Related]
17. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.
Benard A; van Sighem A; Taieb A; Valadas E; Ruelle J; Soriano V; Calmy A; Balotta C; Damond F; Brun-Vezinet F; Chene G; Matheron S;
Clin Infect Dis; 2011 May; 52(10):1257-66. PubMed ID: 21507923
[TBL] [Abstract][Full Text] [Related]
18. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK
Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
